Why the study?
Techniques must be developed to overcome pre-existing immunity to AAV-derived viral vectors and permit vector re-administration if efficacy wanes.
Answers are grounded in this paper and cite their sources.
Developing techniques to evade AAV neutralization is critical for expanding the efficacy and re-administration potential of gene therapies for monogenic disorders.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Earley et al. (2022) conducted a review in Monogenic disorders. Adeno-associated virus (AAV)-derived viral vectors was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: